Background and motive to the Directed Issues

The proceeds from the directed share issues will make it possible to continue development into a phase 2b study in RA with the Company's lead asset resomelagon. The planned study is a dose-determining proof-of-concept study. The plan is to submit an application for a clinical trial, as part of the existing IND application, during the second quarter this year. The results of the study are expected to be presented in the second half of 2025.

The Directed Issue 1 and the Bookbuilding procedure

The subscription price and the total number of new shares in the Directed Issue 1 will be determined through the Bookbuilding procedure, which will be initiated immediately after the publication of this press release. The pricing of the new shares is expected to take place before the commencement of trading on Nasdaq Stockholm at 09:00 CET on 27 March 2024. As the subscription price in the Directed Issue 1 is determined through an accelerated bookbuilding procedure, it is the board of directors' assessment that the marketability of the subscription price is ensured. The board of directors may decide to extend, shorten or cancel the Bookbuilding procedure at any time and thus refrain from carrying out the Directed Issue 1. SynAct Pharma will announce the result of the Bookbuilding procedure through a press release after it has been completed.

The Directed Issue 1 is intended to be carried out with deviation from the shareholders' preferential rights and is decided by the board of directors with the subsequent approval of the general meeting. The reason for the deviation from the shareholders' preferential rights is that the board of directors, after an overall assessment, considers that an issue carried out with deviation from the shareholders' preferential rights is a better alternative for the Company and the Company's shareholders than a rights issue and that it is objectively in the interest of both the Company and its shareholders to carry out the directed issue. The reasons for this are as follows: A rights issue would take longer to implement and thus entail an increased risk of a negative impact on the share price, especially in view of the current market volatility. With a rights issue comes the risk that the issue would not be fully subscribed, whereby a possible guarantee consortium would have to be procured. A directed new issue, on the other hand, is deemed to be able to be carried out at a lower cost and with less complexity, which enables the board of directors and management to focus on the implementation of the Company's new business strategy, which is intended to be implemented as soon as possible. A directed issue also means, unlike a rights issue, that one or several new reputable owners and strategic investors are added to the Company. Existing shareholder Thomas Ringberg is intended to be included in the directed issue, which is motivated by the fact that the owner has shown a long-term interest in the Company, which the board of directors believes contributes to stability for both the Company and its shareholders. In light of the above, it is the board of directors' overall assessment that the reasons for the directed issue outweigh the reasons for a rights issue according to the main rule and the directed issue is thus deemed to be in the interest of both the Company and all shareholders.

The Directed Issue 1 requires, inter alia, that the board of directors of SynAct Pharma, after the completion of the Bookbuilding procedure, resolves on the Directed Issue 1 and resolves to convene an extraordinary general meeting to subsequently approve the board of directors' resolution.

The Directed Issue 2

The board of directors of SynAct Pharma has received a proposal from the Company's major shareholder Thomas Ringberg on the Directed Issue 2. The reasons for the deviation from the shareholders' preferential rights are that Thomas Ringberg, after an overall assessment and careful consideration, considers that an issue carried out with deviation from the shareholders' preferential rights is a better alternative for the Company and the Company's shareholders than a rights issue and that it is objectively in the interest of both the Company and its shareholders to carry out the directed issue. The reasons for this are, inter alia, the following. A rights issue would take longer to carry out and thus entail an increased risk of a negative impact on the share price, especially considering the current market volatility. With a rights issue comes the risk that the issue would not be fully subscribed, whereby a possible guarantee consortium would need to be procured. A directed new issue, on the other hand, is deemed to be able to be made at a lower cost while providing significant capital to the Company for further development and implementation of the Company's new business strategy, which is intended to be implemented as soon as possible. A directed share issue to the Company's board of directors is further motivated by aligning the board's interest with that of the shareholders and further strengthen their commitment to the Company, and enables the board to focus on the implementation of the Company's business strategy, which is considered to contribute to stability for both the Company and its other shareholders. Thomas Ringberg’s overall assessment is that the reasons for the directed issue outweigh the reasons for a rights issue according to the main rule and the directed issue is thus considered to be in the interest of both the Company and all shareholders.

Assuming that the board of directors resolves on the Directed Issue 1, the board of directors intends to convene an extraordinary general meeting in order for the general meeting to decide on Thomas Ringberg’s proposal. The subscription price in the Directed Issue 2 shall in accordance with Thomas Ringberg’s proposal shall correspond to the subscription price determined in the Bookbuilding procedure. The Directed Issue 2 shall, in accordance with the proposal be directed to the members of the board of directors Anders Kronborg, Sten Scheiby, Sten Sörensen, via his company Bridge Consulting AB, and Jeppe Øvlesen, via his company Quantass ApS.

The board members intend to subscribe for the shares if the Directed Issue 2 is carried out.

The Directed Issue 3

The board of directors further intends, provided that the board of directors resolves on Directed Issue 1, to resolve on Directed Issue 3 subject to the subsequent approval by the general meeting. The reasons for the deviation from the shareholders' preferential rights are that the board of directors, after an overall assessment and careful consideration, believes that an issue carried out with deviation from the shareholders' preferential rights is a better alternative for the Company and the Company's shareholders than a rights issue and that it is objectively in the interest of both the Company and its shareholders to carry out the directed issue. The reasons for this are, inter alia, the following. A rights issue would take longer to carry out and thus entail an increased risk of a negative impact on the share price, especially considering the current market volatility. With a rights issue comes the risk that the issue would not be fully subscribed, whereby a possible underwriting consortium would need to be procured. A directed new share issue, on the other hand, is deemed to be able to be carried out at a lower cost and with less complexity, while at the same time providing significant capital to the Company, which enables the board of directors and management to focus on the implementation of the Company's new business strategy, which is intended to be implemented as soon as possible. A directed share issue to the management is further motivated by further aligning the management's interest with that of the shareholders and strengthen their commitment to the Company, which is considered to contribute to stability for both the Company and its other shareholders. The board of directors' overall assessment is that the reasons for the directed issue outweigh the reasons for a rights issue according to the main rule and the directed issue is thus considered to be in the interest of both the Company and all shareholders.

The board of directors' intention is that the subscription price in the Directed Issue 3 shall correspond to the subscription price determined in the Bookbuilding procedure. The board of directors intends that the Directed Issue 3 shall be directed to Thomas Jonassen (CSO), via his company TJ Biotech Holding ApS, Thomas Boesen (COO), via his company Boesen Biotech ApS and Björn Westberg (CFO), via his company BTB Consult AB.

These members of the management of the Company have indicated that they intend to subscribe for the shares if the Directed Issue 3 is completed.

Lock-up commitments

In connection with the Directed Issues, Anders Kronborg, Sten Scheibye, Sten Sörensen, Jeppe Øvlesen, Thomas Jonassen, Thomas Boesen and Björn Westberg intend to contractually undertake towards Sedermera, with customary exceptions, not to sell or carry out other transactions with equivalent effect to a sale without, in each case, first obtaining a written consent from Sedermera. The decision to provide such written consent is decided by Sedermera and an assessment is made in each individual case. Granted consent can be based on both individual and business reasons. The lock-up commitments are intended to cover the shares held prior to the Directed Issues and shares received in connection with the Directed Issues. The lock-up period lasts for 180 days from this announcement of the Directed Issues.

Advisers

In connection with the Directed Issues, the Company has engaged Sedermera as Sole Bookrunner and Advokatfirma DLA Piper Sweden KB as legal advisor. Nordic Issuing act issuing agent.

Lund, Sweden, March 26, 2024

SynAct Pharma AB

For additional information, please contact
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com

For further information on the Directed Issues, please contact:
Sedermera Corporate Finance AB
Phone: +46 40 615 14 10
E-mail: cf@sedermera.se
Website: www.sedermera.se

About SynAct Pharma AB
SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and anti-inflammatory activity in autoimmune and inflammatory diseases to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com.

Important information

The information contained in this press release is not for release, publication or distribution, directly or indirectly, in or into the United States, Russia, Belarus, Australia, Canada, Japan, India, South Africa, Hong Kong, Singapore or any other state or jurisdiction where such release, publication or distribution would be unlawful or would require additional prospectuses, registration or other measures than those required by Swedish law.

This press release is for information purposes only and does not constitute an offer to sell or issue, purchase or subscribe for any of the securities described herein (together the "Securities") or any other financial instrument in SynAct Pharma AB. This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. The Company has not authorized any offer to the public of securities in any member state of the EEA and no prospectus has been or will be prepared in connection with the Directed Issues.

This press release does not constitute an offer to sell or an offer, or a solicitation of an offer, to buy or subscribe for shares issued by the Company in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. Actions in violation of the restrictions may constitute a violation of applicable securities laws.

The Securities referred to in this press release have not been and will not be registered under any applicable securities laws of the United States, Russia, Belarus, Australia, Canada, Japan, India, South Africa, Hong Kong, Singapore and, subject to certain exceptions, may not be offered or sold to or within, or for the account or benefit of, any person registered in any of these countries. The Company has not made any offer to subscribe for or acquire the Securities referred to in this press release to the public in any country.

None of the Securities have been or will be registered under the United States Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any state or other jurisdiction of the United States and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with other applicable securities laws. There will be no public offering of any of the Securities in the United States.

In the EEA Member States (each such EEA Member State a "Relevant State"), this press release and the information contained herein is only intended for and directed at qualified investors as defined in the Prospectus Regulation. The securities referred to in this press release are not being offered to the public in any Relevant State and are only available to qualified investors except in accordance with the exemptions in the Prospectus Regulation. Persons in any Relevant State who are not qualified investors should not take any action based on this press release nor rely on it.

In the United Kingdom, the information contained in this press release and any other materials in relation to the Securities is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); (ii) high net worth entities falling within Article 49 (2)(a) to (d) of the Order; or (iii) such other persons to whom such investment or investment activity may lawfully be directed pursuant to the Order (all such persons together being referred to as “relevant persons”);. In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

This notice does not constitute an investment recommendation. The price and value of securities and any income derived from securities may go down as well as up and you may lose your entire investment. Past performance is not an indication of future performance. The information in this communication cannot be relied upon as an indication of future performance.

This press release contains certain information that reflects SynAct Pharma AB's current view of future events and financial and operational development. Words such as "intends", "believes", "expects", "may", "plans", "estimates" and other expressions that imply indications or predictions of future developments or trends, and that are not based on historical facts, constitute forward-looking information and reflect SynAct Pharma AB's beliefs and expectations and involve a number of risks, uncertainties and assumptions that could cause actual events and results to differ materially from any anticipated future events or performance expressed or implied by the forward-looking statement. The information in this press release is subject to change without notice and, except as required by applicable law, SynAct Pharma AB does not undertake any responsibility or obligation to publicly update or revise any of the forward-looking statements contained in it, nor does it intend to do so. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. As a result of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements as a prediction of actual future events or otherwise.